Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
Wenhao Shi, Tingting Jiang, Paolo Giovanni Nuciforo et al. · Annals of Oncology · 2016
Cited by 76 works. doi:10.1093/annonc/mdw434 Open-access PDF
Authors
- Wenhao Shi
- Tingting Jiang
- Paolo Giovanni Nuciforo
- Christos Hatzis
- Eileen McCormick Holmes
- Nadia Harbeck
- Christos Sotiriou
- L. Peña
- Sherene Loi
- Daniela D. Rosa
- Andrew M. Wardley
- Takayuki Ueno
- José Roberto Freitas Rossari
- Holger Eidtmann
- Alison A. Armour
- Martine J Piccart
- David L. Rimm
- José Baselga
- Lajos Pusztai
References
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
- The Cancer Genome Atlas Pan-Cancer analysis project
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma
- PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
- Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
- Anti-RhoA and Anti-RhoC siRNAs Inhibit the Proliferation and Invasiveness of MDA-MB-231 Breast Cancer Cells in Vitro and in Vivo